1. On page 2, in the last sentence of the first paragraph under the subheading BAnimals groups^, B0.25 mL/Kg^should be B0.25 ml/Kg^.
1. On page 2, in the last sentence of the first paragraph under the subheading BAnimals groups^, B0.25 mL/Kg^should be B0.25 ml/Kg^.
2. On page 4, under the subheading BStatistical analysis^, BSE^should be BSEM^.
3. On page 7, under BDiscussion^section, the paragraph that reads:
BP2X 3 receptors are present mainly in small-to mediumsized neurons in the DRG. Selective distribution in small primary afferent neurons suggests a contributing role of the P2X 3 receptor in nociception and pain [42] . Activation of the P2X 3 receptor contributes to pain and hyperalgesia [43] . This study showed that the upregulated expression of the P2X 3 receptor was followed by an enhancement of mechanical and thermal hyperalgesia, resulting in the subsequent activation of the P2X 3 receptor in the T2DM DRG. Cytokines liberated in the setting of peripheral inflammation contribute to pain. Thus, NONRATT021972 siRNA treatment could reduce the serum levels of TNF-α in T2DM rats, decrease the up-regulated expression of the P2X 3 receptor in DRG, and relieve P2X 3 receptor-mediated DNP in T2DM rats. This finding further confirmed that NONRATT021972 might be involved in the pathological process of T2DM^.
should be corrected to: BP2X 3 receptors are present mainly in small-to mediumsized neurons in the DRG. Selective distribution in small primary afferent neurons suggests a contributing role of the P2X 3 receptor in nociception and pain [42] . Activation of the P2X 3 receptor contributes to pain and hyperalgesia [43] . This study showed that the upregulated expression of the P2X 3 receptor was followed by an enhancement of mechanical and thermal hyperalgesia, resulting in the subsequent activation of the P2X 3 receptor in the T2DM DRG. Thus, sinomenine treatment could decrease the up-regulated expression of the P2X 3 receptor in DRG, and relieve P2X 3 receptormediated DNP in T2DM rats^.
